
SkylineDx at the forefront of a genomic revolution
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
Discover moreLearn more about MMprofiler™, the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.
Learn moreLatest news
31 Jan 2018
SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma
Rotterdam, the Netherlands, January 31, 2018 – SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the colla...
Upcoming Events
28 Mar 2018 - 30 Mar 2018, Radboud University Medical Center, Nijmegen, The Netherlands
6th International Workshop on Cancer Genetic & Cytogenetic Diagnostics
28 Mar 2018 - 30 Mar 2018, Novatel Paris Centre Tour Eiffel, Paris, France
The Fourth World Congress on Controversies in Multiple Myeloma (COMy)
19 Apr 2018 - 21 Apr 2018, Lingotto Conference Center, Turin, Italy
1st European Myeloma Network Meeting